Checkmate Pharmaceuticals, Inc. (CMPI) SEC Filing 8-K Material Event for the period ending Tuesday, May 31, 2022

Checkmate Pharmaceuticals, Inc.

CIK: 1651431 Ticker: CMPI

View differences made from one to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Checkmate Pharmaceuticals, Inc..


Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CMPI
CIK: 1651431
Form Type: 8-K Corporate News
Accession Number: 0001104659-22-066299
Submitted to the SEC: Tue May 31 2022 9:16:52 AM EST
Accepted by the SEC: Tue May 31 2022
Period: Tuesday, May 31, 2022
Industry: Biological Products No Disgnostic Substances
  1. Bylaw Change
  2. Change in Assets
  3. Change in Control
  4. Event for Officers
  5. Financial Exhibit
  6. Listing Status
  7. Security Holders Change

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: